FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Moderna presentation on the vaccine from ReSViNET Conference (RSVVW 2023):<p><a href="https://s29.q4cdn.com/435878511/files/doc_presentations/2023/02/rsvvw-p301-ia-oral-presentation_final-update.pdf" rel="nofollow">https://s29.q4cdn.com/435878511/files/doc_presentations/2023...</a><p>some commentary summarized from alexberenson.substack.com :<p><i>Nine people who received the shot got RSV. Fifty-five who received the placebo did. Thus the 17,500 shots prevented 46 cases of RSV.<p>It shows people who received the jab instead of the placebo reported an extra 10,156 side effects such as headache or fatigue. Those side effects included an extra 455 severe effects, rated as Grade 3 or worse.<p>Side effects are rated on a five-point scale, with Grade 5 being death and Grade 4 usually requiring immediate medical treatment and hospitalization. Grade 3 side effects are defined as “severe or medically significant.”<p>For example, a Grade 3 fever is usually defined as over about 102 degrees, while a Grade 4 is over 104.<p>In other words, a single Grade 3 side effect is likely to be considerably more severe than a case of RSV for most adults. Again, Moderna’s shot caused 10 of those side effects for every RSV infection it prevented.</i><p><a href="https://alexberenson.substack.com/p/how-can-modernas-rsv-jab-be-approvable" rel="nofollow">https://alexberenson.substack.com/p/how-can-modernas-rsv-jab...</a>